Suppr超能文献

年轻于 45 岁的子宫内膜癌患者的保守性治疗的最新进展。

Updates on conservative management of endometrial cancer in patients younger than 45 years.

机构信息

Department of Gynecologic Oncology, Sanatorio Allende, Córdoba, Argentina.

Department of Gynecologic Oncology, Sanatorio Allende, Córdoba, Argentina.

出版信息

Gynecol Oncol. 2021 Jun;161(3):802-809. doi: 10.1016/j.ygyno.2021.04.017. Epub 2021 Apr 20.

Abstract

Endometrial cancer is the most common gynecologic malignancy in developed country. Women under the age of 40 represent 5% of all endometrial cancer and the majority are nulliparous at the time of diagnosis. The aim of this review was to compare oncologic and fertility outcomes among different fertility-preserving therapies in patients under 45 years of age with grade 1 or 2 endometrial cancer. A systematic review was conducted, the MEDLINE, EMBASE, and CINAHL databases were searched for articles published during the period from January 2010 through January 2020 in accordance with PRISMA guidelines, using the terms endometrial cancer, fertility sparing treatment and conservative treatment. A total of 661 patients in 38 studies were included. The median age was 32.3 years (range 13--43). Regardless of the primary treatment, it is always accompanied by systemic or local hormonal treatment. The median follow-up time was 47.92 months (range 1-412), 54.9 months (range 3.4-412) for the progesterone group, 38.97 months (range 3-172) for the hysteroscopic resection group and 23.11 months (range 1-115.5) for the Levonorgestrel Intrauterine Device group. The overall complete response rate was 79.4%, [Hysteroscopic Resection: 90%, hormonal treatment: 77.7%, and Levonorgestrel Intrauterine Device: 71.3%] The p = 0.02 when the primary treatment is Hysteroscopic resection, always followed by hormonal therapy either oral progesterone or Levonorgestrel Intrauterine Device. Patients who had tumor resection had lower progression than those who received hormonal treatment or Levonorgestrel Intrauterine Device 3.5% vs. 12.1% vs. 19.5% respectively (p = 0.03). The complete response time was higher in the Hysteroscopic Resection group (p = 0.04) with fewer patients undergoing hysterectomy (p = 0.0001). Patients who underwent Hysteroscopic Resection had higher pregnancy rates compared to medical treatment or Levonorgestrel Intrauterine Device, 34.5%, 27.6% and 18.4%, respectively (p = 0.002). CONCLUSION: Patients who underwent Hysteroscopic Resection followed progestogens agent was associated to a better complete response, high pregnancy rates and minor numbers of hysterectomies.

摘要

子宫内膜癌是发达国家最常见的妇科恶性肿瘤。40 岁以下的女性占所有子宫内膜癌的 5%,大多数在诊断时为未产妇。本综述的目的是比较不同生育保护治疗方法在 45 岁以下患有 1 级或 2 级子宫内膜癌的患者中的肿瘤学和生育结局。按照 PRISMA 指南,对 2010 年 1 月至 2020 年 1 月期间发表的文章进行了系统评价,使用了子宫内膜癌、保留生育治疗和保守治疗等术语,对 MEDLINE、EMBASE 和 CINAHL 数据库进行了检索。共纳入 38 项研究的 661 例患者。中位年龄为 32.3 岁(范围 13-43 岁)。无论采用何种主要治疗方法,都需要进行全身或局部激素治疗。中位随访时间为 47.92 个月(范围 1-412),孕激素组为 54.9 个月(范围 3.4-412),宫腔镜切除术组为 38.97 个月(范围 3-172),左炔诺孕酮宫内节育器组为 23.11 个月(范围 1-115.5)。总体完全缓解率为 79.4%[宫腔镜切除术:90%,激素治疗:77.7%,左炔诺孕酮宫内节育器:71.3%]。当主要治疗方法为宫腔镜切除术,且始终辅以孕激素治疗(口服孕激素或左炔诺孕酮宫内节育器)时,p = 0.02。肿瘤切除患者的进展率低于接受激素治疗或左炔诺孕酮宫内节育器的患者(分别为 3.5%、12.1%和 19.5%)(p = 0.03)。宫腔镜切除术组的完全缓解时间较短(p = 0.04),且接受子宫切除术的患者较少(p = 0.0001)。与药物治疗或左炔诺孕酮宫内节育器相比,接受宫腔镜切除术的患者的妊娠率更高,分别为 34.5%、27.6%和 18.4%(p = 0.002)。结论:接受宫腔镜切除术加孕激素治疗的患者,完全缓解率高、妊娠率高、子宫切除术比例低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验